With 64% of the funds reporting, the Composite’s gain is higher than August’s 0.9% (See Hedge Funds Return 0.94% in August ) and the MSCI World Equity Index, which up 0.5%. For the year, the Composite index is up 11.1%, underperforming its World counterpart’s 14.8% return, according to a MSCI news release.
Compared to the World Sovereign Debt Index, which returned a 5.7% gain in September, the Composite index was worse for the month. For the year, the World Sovereign Debt Index has now returned 9.3%.
September’s largest process group gainer, based on 54% of funds reporting, was the Multi-Process Group, up 2.3%. Multi-Process, strategies that focus on spread relationships between pricing components of financial assets or commodities, has now returned 15.2% year-to-date.
The remain four indexes also posted positive monthly returns, lead by the Security Selection and Specialist Credit Indices’ 1.8%-September returns. Security Selection, those managers who combine long positions and short sales with the aim of benefiting from their ability in selecting investments while offsetting systematic market risks, has now returned 14% year to date on a 63% reporting rate while Specialist Credit, those funds that seek to lend to credit-sensitive issuers, has now returned 15.7% year to date based on 59% of funds reporting.
Rounding out the list was a 1.6% gain notched by the Relative Value Index and a 1.1% September return posted by the Directional Trading Index. With 74% of funds reporting, Directional Trading, strategies based upon speculating on the direction of market prices of currencies, commodities, equities, and bonds in the futures and cash markets, is up 7.8% year to date. Similarly, Relative Value is also positive for the year 6.2%, with 62% of funds reporting.
The MSCI Hedge Fund Indices are composed of more than 190 indices. More than 1,800 hedge funds have agreed to participate in the database and there are over 1,600 hedge funds currently in the MSCI Hedge Fund Indices and Database.
« Employee Stock Options Grants at Life Sciences Companies Reduced by 30%